Ovarian Cancer – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Ovarian Cancer – Pipeline Review, H2 2016’, provides an overview of the Ovarian Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ovarian Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Ovarian Cancer

The report reviews pipeline therapeutics for Ovarian Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Ovarian Cancer therapeutics and enlists all their major and minor projects

The report assesses Ovarian Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Ovarian Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Ovarian Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ovarian Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3-V Biosciences Inc

4SC AG

AB Science SA

AbbVie Inc

AbGenomics International Inc

Acetylon Pharmaceuticals Inc

Adaptimmune Therapeutics Plc

Adgero Biopharmaceuticals Inc

Aduro BioTech Inc

Advanced Accelerator Applications SA

Advanced Cancer Therapeutics

Advaxis Inc

Advenchen Laboratories LLC

Aeterna Zentaris Inc

Alchemia Ltd

Alethia Biotherapeutics Inc

Almac Discovery Ltd

Alpha Cancer Technologies Inc

Alteogen Inc

Ambrx Inc

Amgen Inc

Anavex Life Sciences Corp

ANP Technologies Inc

AntiCancer Inc

Antoxis Ltd

Apac Biotech Pvt Ltd

Aphios Corp

Aposense Ltd

Aprea AB

Aptevo Therapeutics Inc

arGEN-X BV

ARMO Biosciences Inc

Armour Therapeutics Inc

Arno Therapeutics Inc

Arog Pharmaceuticals Inc

ArQule Inc

Arrien Pharmaceuticals LLC

Arvinas Inc

Ascentage Pharma Group Corp Ltd

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

Athenex Inc

ATLAB Pharma SAS

AVEO Pharmaceuticals Inc

Avipep Pty Ltd

Azaya Therapeutics Inc

Basilea Pharmaceutica Ltd

Bavarian Nordic A/S

Bayer AG

BeiGene Ltd

Bio-Path Holdings Inc

BioCancell Ltd

BioMoti Ltd

Bionomics Ltd

BioNTech AG

Biscayne Pharmaceuticals Inc

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Company

Calithera Biosciences Inc

CASI Pharmaceuticals Inc

Cavion LLC

Cellceutix Corp

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Cellular Biomedicine Group Inc

Celon Pharma SA

Celprogen Inc

Celsion Corp

Celyad SA

Ceronco Biosciences

CerRx Inc

Cerulean Pharma Inc

Chipscreen Biosciences Ltd

Cielo Therapeutics Inc

Clovis Oncology Inc

CohBar Inc

Coherus BioSciences Inc

Commence Bio Inc

Compliment Corp

Corcept Therapeutics Inc

Critical Outcome Technologies Inc

CTI BioPharma Corp

Cyclacel Pharmaceuticals Inc

CytRx Corp

CZ BioMed Corp

Deciphera Pharmaceuticals LLC

DEKK-TEC Inc

DelMar Pharmaceuticals Inc

Dr. Reddy's Laboratories Ltd

Ecrins Therapeutics SAS

EirGenix Inc

Eisai Co Ltd

Eli Lilly and Company

Endocyte Inc

EntreChem SL

Epigen Biosciences Inc

Esperance Pharmaceuticals Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

Five Prime Therapeutics Inc

Fujifilm Corp

Galena Biopharma Inc

GamaMabs Pharma SA

Ganymed Pharmaceuticals AG

Gene Techno Science Co Ltd

Genelux Corp

Genentech Inc

Generex Biotechnology Corp

Genisphere Inc

Genmab A/S

Genor BioPharma Co Ltd

Gero Corp

Gilead Sciences Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

GlycoNex Inc

Glycotope GmbH

GP Pharm SA

Gradalis Inc

GW Pharmaceuticals Plc

Halozyme Therapeutics Inc

Hanmi Pharmaceuticals Co Ltd

HEC Pharm Co Ltd

Hemispherx Biopharma Inc

Horizon Pharma Plc

Ideaya Biosciences Inc

Ignyta Inc

Ildong Pharmaceutical Co Ltd

IMMD Inc

Immune Design Corp

Immune Pharmaceuticals Inc

Immune Therapeutics Inc

Immunocore Ltd

ImmunoGen Inc

Immunomedics Inc

Immunovaccine Inc

Incyte Corp

Inflection Biosciences Ltd

Innate Immunotherapeutics Ltd

Innate Pharma SA

Inovio Pharmaceuticals Inc

INSYS Therapeutics Inc

Inventiva

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

Juno Therapeutics Inc

Karyopharm Therapeutics Inc

Komipharm International Co Ltd

Kyowa Hakko Kirin Co Ltd

Laboratoire HRA Pharma

Lantern Pharma Inc

LegoChem Biosciences Inc

Lidds AB

Lion Biotechnologies Inc

Lixte Biotechnology Holdings Inc

Lymphocyte Activation Technologies SA

Mabion SA

MabVax Therapeutics Holdings Inc

MacroGenics Inc

Mateon Therapeutics Inc

MaxiVAX SA

Mebiopharm Co Ltd

Medestea Research & Production SpA

MediaPharma srl

MedImmune LLC

Medivation Inc

Merck & Co Inc

Merck KGaA

Mersana Therapeutics Inc

Merus NV

Microlin Bio, Inc.

Millennium Pharmaceuticals Inc

Minerva Biotechnologies Corp

Molecular Partners AG

Moleculin Biotech Inc

MolMed SpA

Monopar Therapeutics LLC

Morphotek Inc

Mycenax Biotech Inc

Natco Pharma Ltd

Nektar Therapeutics

Nemucore Medical Innovations Inc

Neovacs SA

Nerviano Medical Sciences Srl

Neurimmune Holding AG

Northwest Biotherapeutics Inc

Novartis AG

NovaTarg Therapeutics Inc

Noviga Research AB

Novogen Ltd

NuCana BioMed Ltd

Oasmia Pharmaceutical AB

OBI Pharma Inc

Omeros Corp

Omnitura Therapeutics Inc

OncBioMune Pharmaceuticals Inc

Oncobiologics Inc

Oncodesign SA

OncoHoldings Inc

Oncolix Inc

Oncolytics Biotech Inc

OncoMed Pharmaceuticals Inc

Oncopeptides AB

OncoTartis Inc

Oncternal Therapeutics Inc

Ono Pharmaceutical Co Ltd

Optimum Therapeutics LLC

ORCA Therapeutics BV

OSE Immunotherapeutics

Oxford BioMedica Plc

OXIS International Inc

Pangaea Biotech SL

Panther Biotechnology Inc

Patrys Ltd

PDS Biotechnology Corp

PEP-Therapy SAS

Pfizer Inc

Pharma Mar SA

PharmAust Ltd

Pharmicell Co Ltd

Plexxikon Inc

Polaris Pharmaceuticals Inc

Precision Biologics Inc

Prima BioMed Ltd

Propanc Health Group Corp

PsiOxus Therapeutics Ltd

Puma Biotechnology Inc

Radius Health Inc

Recepta Biopharma SA

Rexahn Pharmaceuticals Inc

Rgenix Inc

Richter Gedeon Nyrt

Rigontec GmbH

Rosetta Genomics Ltd

Sanofi

Sanofi Pasteur SA

Sapvax

SATT North SAS

Sellas Inc

Senhwa Biosciences Inc

Shenzen SiBiono GeneTech Co Ltd

Siamab Therapeutics Inc

Sigma-Tau SpA

SOM Biotech SL

Soricimed Biopharma Inc

Sorrento Therapeutics Inc

Sotio as

Spectrum Pharmaceuticals Inc

Sphaera Pharma Pvt Ltd

Starpharma Holdings Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 13

Ovarian Cancer Overview 14

Therapeutics Development 15

Ovarian Cancer - Therapeutics under Development by Companies 17

Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes 41

Ovarian Cancer - Pipeline Products Glance 44

Ovarian Cancer - Products under Development by Companies 48

Ovarian Cancer - Products under Investigation by Universities/Institutes 81

Ovarian Cancer - Companies Involved in Therapeutics Development 85

Ovarian Cancer - Therapeutics Assessment 371

Drug Profiles 451

Ovarian Cancer - Dormant Projects 1775

Ovarian Cancer - Discontinued Products 1809

Ovarian Cancer - Product Development Milestones 1816

Appendix 1829

List of Tables

List of Tables

Number of Products under Development for Ovarian Cancer, H2 2016 72

Number of Products under Development for Ovarian Cancer – Comparative Analysis, H2 2016 73

Number of Products under Development by Companies, H2 2016 75

Number of Products under Development by Companies, H2 2016 (Contd..1) 76

Number of Products under Development by Companies, H2 2016 (Contd..2) 77

Number of Products under Development by Companies, H2 2016 (Contd..3) 78

Number of Products under Development by Companies, H2 2016 (Contd..4) 79

Number of Products under Development by Companies, H2 2016 (Contd..5) 80

Number of Products under Development by Companies, H2 2016 (Contd..6) 81

Number of Products under Development by Companies, H2 2016 (Contd..7) 82

Number of Products under Development by Companies, H2 2016 (Contd..8) 83

Number of Products under Development by Companies, H2 2016 (Contd..9) 84

Number of Products under Development by Companies, H2 2016 (Contd..10) 85

Number of Products under Development by Companies, H2 2016 (Contd..11) 86

Number of Products under Development by Companies, H2 2016 (Contd..12) 87

Number of Products under Development by Companies, H2 2016 (Contd..13) 88

Number of Products under Development by Companies, H2 2016 (Contd..14) 89

Number of Products under Development by Companies, H2 2016 (Contd..15) 90

Number of Products under Development by Companies, H2 2016 (Contd..16) 91

Number of Products under Development by Companies, H2 2016 (Contd..17) 92

Number of Products under Development by Companies, H2 2016 (Contd..18) 93

Number of Products under Development by Companies, H2 2016 (Contd..19) 94

Number of Products under Development by Companies, H2 2016 (Contd..20) 95

Number of Products under Development by Companies, H2 2016 (Contd..21) 96

Number of Products under Development by Companies, H2 2016 (Contd..22) 97

Number of Products under Investigation by Universities/Institutes, H2 2016 98

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 99

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 100

Comparative Analysis by Late Stage Development, H2 2016 101

Comparative Analysis by Clinical Stage Development, H2 2016 102

Comparative Analysis by Early Stage Development, H2 2016 103

Comparative Analysis by Unknown Stage Development, H2 2016 104

Products under Development by Companies, H2 2016 105

Products under Development by Companies, H2 2016 (Contd..1) 106

Products under Development by Companies, H2 2016 (Contd..2) 107

Products under Development by Companies, H2 2016 (Contd..3) 108

Products under Development by Companies, H2 2016 (Contd..4) 109

Products under Development by Companies, H2 2016 (Contd..5) 110

Products under Development by Companies, H2 2016 (Contd..6) 111

Products under Development by Companies, H2 2016 (Contd..7) 112

Products under Development by Companies, H2 2016 (Contd..8) 113

Products under Development by Companies, H2 2016 (Contd..9) 114

Products under Development by Companies, H2 2016 (Contd..10) 115

Products under Development by Companies, H2 2016 (Contd..11) 116

Products under Development by Companies, H2 2016 (Contd..12) 117

Products under Development by Companies, H2 2016 (Contd..13) 118

Products under Development by Companies, H2 2016 (Contd..14) 119

Products under Development by Companies, H2 2016 (Contd..15) 120

Products under Development by Companies, H2 2016 (Contd..16) 121

Products under Development by Companies, H2 2016 (Contd..17) 122

Products under Development by Companies, H2 2016 (Contd..18) 123

Products under Development by Companies, H2 2016 (Contd..19) 124

Products under Development by Companies, H2 2016 (Contd..20) 125

Products under Development by Companies, H2 2016 (Contd..21) 126

Products under Development by Companies, H2 2016 (Contd..22) 127

Products under Development by Companies, H2 2016 (Contd..23) 128

Products under Development by Companies, H2 2016 (Contd..24) 129

Products under Development by Companies, H2 2016 (Contd..25) 130

Products under Development by Companies, H2 2016 (Contd..26) 131

Products under Development by Companies, H2 2016 (Contd..27) 132

Products under Development by Companies, H2 2016 (Contd..28) 133

Products under Development by Companies, H2 2016 (Contd..29) 134

Products under Development by Companies, H2 2016 (Contd..30) 135

Products under Development by Companies, H2 2016 (Contd..31) 136

Products under Development by Companies, H2 2016 (Contd..32) 137

Products under Investigation by Universities/Institutes, H2 2016 138

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 139

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 140

Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 141

Ovarian Cancer – Pipeline by 3-V Biosciences Inc, H2 2016 142

Ovarian Cancer – Pipeline by 4SC AG, H2 2016 143

Ovarian Cancer – Pipeline by AB Science SA, H2 2016 144

Ovarian Cancer – Pipeline by AbbVie Inc, H2 2016 145

Ovarian Cancer – Pipeline by AbGenomics International Inc, H2 2016 146

Ovarian Cancer – Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 147

Ovarian Cancer – Pipeline by Adaptimmune Therapeutics Plc, H2 2016 148

Ovarian Cancer – Pipeline by Adgero Biopharmaceuticals Inc, H2 2016 149

Ovarian Cancer – Pipeline by Aduro BioTech Inc, H2 2016 150

Ovarian Cancer – Pipeline by Advanced Accelerator Applications SA, H2 2016 151

Ovarian Cancer – Pipeline by Advanced Cancer Therapeutics, H2 2016 152

Ovarian Cancer – Pipeline by Advaxis Inc, H2 2016 153

Ovarian Cancer – Pipeline by Advenchen Laboratories LLC, H2 2016 154

Ovarian Cancer – Pipeline by Aeterna Zentaris Inc, H2 2016 155

Ovarian Cancer – Pipeline by Alchemia Ltd, H2 2016 156

Ovarian Cancer – Pipeline by Alethia Biotherapeutics Inc, H2 2016 157

Ovarian Cancer – Pipeline by Almac Discovery Ltd, H2 2016 158

Ovarian Cancer – Pipeline by Alpha Cancer Technologies Inc, H2 2016 159

Ovarian Cancer – Pipeline by Alteogen Inc, H2 2016 160

Ovarian Cancer – Pipeline by Ambrx Inc, H2 2016 161

Ovarian Cancer – Pipeline by Amgen Inc, H2 2016 162

Ovarian Cancer – Pipeline by Anavex Life Sciences Corp, H2 2016 163

Ovarian Cancer – Pipeline by ANP Technologies Inc, H2 2016 164

Ovarian Cancer – Pipeline by AntiCancer Inc, H2 2016 165

Ovarian Cancer – Pipeline by Antoxis Ltd, H2 2016 166

Ovarian Cancer – Pipeline by Apac Biotech Pvt Ltd, H2 2016 167

Ovarian Cancer – Pipeline by Aphios Corp, H2 2016 168

Ovarian Cancer – Pipeline by Aposense Ltd, H2 2016 169

Ovarian Cancer – Pipeline by Aprea AB, H2 2016 170

Ovarian Cancer – Pipeline by Aptevo Therapeutics Inc, H2 2016 171

Ovarian Cancer – Pipeline by arGEN-X BV, H2 2016 172

Ovarian Cancer – Pipeline by ARMO Biosciences Inc, H2 2016 173

Ovarian Cancer – Pipeline by Armour Therapeutics Inc, H2 2016 174

Ovarian Cancer – Pipeline by Arno Therapeutics Inc, H2 2016 175

Ovarian Cancer – Pipeline by Arog Pharmaceuticals Inc, H2 2016 176

Ovarian Cancer – Pipeline by ArQule Inc, H2 2016 177

Ovarian Cancer – Pipeline by Arrien Pharmaceuticals LLC, H2 2016 178

Ovarian Cancer – Pipeline by Arvinas Inc, H2 2016 179

Ovarian Cancer – Pipeline by Ascentage Pharma Group Corp Ltd, H2 2016 180

Ovarian Cancer – Pipeline by Astellas Pharma Inc, H2 2016 181

Ovarian Cancer – Pipeline by Astex Pharmaceuticals Inc, H2 2016 182

Ovarian Cancer – Pipeline by AstraZeneca Plc, H2 2016 183

Ovarian Cancer – Pipeline by Atara Biotherapeutics Inc, H2 2016 184

Ovarian Cancer – Pipeline by Athenex Inc, H2 2016 185

Ovarian Cancer – Pipeline by ATLAB Pharma SAS, H2 2016 186

Ovarian Cancer – Pipeline by AVEO Pharmaceuticals Inc, H2 2016 187

Ovarian Cancer – Pipeline by Avipep Pty Ltd, H2 2016 188

Ovarian Cancer – Pipeline by Azaya Therapeutics Inc, H2 2016 189

Ovarian Cancer – Pipeline by Basilea Pharmaceutica Ltd, H2 2016 190

Ovarian Cancer – Pipeline by Bavarian Nordic A/S, H2 2016 191

Ovarian Cancer – Pipeline by Bayer AG, H2 2016 192

Ovarian Cancer – Pipeline by BeiGene Ltd, H2 2016 193

Ovarian Cancer – Pipeline by Bio-Path Holdings Inc, H2 2016 194

Ovarian Cancer – Pipeline by BioCancell Ltd, H2 2016 195

Ovarian Cancer – Pipeline by BioMoti Ltd, H2 2016 196

Ovarian Cancer – Pipeline by Bionomics Ltd, H2 2016 197

Ovarian Cancer – Pipeline by BioNTech AG, H2 2016 198

Ovarian Cancer – Pipeline by Biscayne Pharmaceuticals Inc, H2 2016 199

Ovarian Cancer – Pipeline by Boehringer Ingelheim GmbH, H2 2016 200

Ovarian Cancer – Pipeline by Boston Biomedical Inc, H2 2016 201

Ovarian Cancer – Pipeline by Bristol-Myers Squibb Company, H2 2016 202

Ovarian Cancer – Pipeline by Calithera Biosciences Inc, H2 2016 203

Ovarian Cancer – Pipeline by CASI Pharmaceuticals Inc, H2 2016 204

Ovarian Cancer – Pipeline by Cavion LLC, H2 2016 205

Ovarian Cancer – Pipeline by Cellceutix Corp, H2 2016 206

Ovarian Cancer – Pipeline by Celldex Therapeutics Inc, H2 2016 207

Ovarian Cancer – Pipeline by Cellectar Biosciences Inc, H2 2016 208

Ovarian Cancer – Pipeline by Cellular Biomedicine Group Inc, H2 2016 209

Ovarian Cancer – Pipeline by Celon Pharma SA, H2 2016 210

Ovarian Cancer – Pipeline by Celprogen Inc, H2 2016 211

Ovarian Cancer – Pipeline by Celsion Corp, H2 2016 212

Ovarian Cancer – Pipeline by Celyad SA, H2 2016 213

Ovarian Cancer – Pipeline by Ceronco Biosciences, H2 2016 214

Ovarian Cancer – Pipeline by CerRx Inc, H2 2016 215

Ovarian Cancer – Pipeline by Cerulean Pharma Inc, H2 2016 216

Ovarian Cancer – Pipeline by Chipscreen Biosciences Ltd, H2 2016 217

Ovarian Cancer – Pipeline by Cielo Therapeutics Inc, H2 2016 218

Ovarian Cancer – Pipeline by Clovis Oncology Inc, H2 2016 219

Ovarian Cancer – Pipeline by CohBar Inc, H2 2016 220

Ovarian Cancer – Pipeline by Coherus BioSciences Inc, H2 2016 221

Ovarian Cancer – Pipeline by Commence Bio Inc, H2 2016 222

Ovarian Cancer – Pipeline by Compliment Corp, H2 2016 223

List of Figures

List of Figures

Number of Products under Development for Ovarian Cancer, H2 2016 72

Number of Products under Development for Ovarian Cancer – Comparative Analysis, H2 2016 73

Number of Products under Development by Companies, H2 2016 74

Number of Products under Investigation by Universities/Institutes, H2 2016 98

Comparative Analysis by Late Stage Development, H2 2016 101

Comparative Analysis by Clinical Stage Development, H2 2016 102

Comparative Analysis by Early Stage Products, H2 2016 103

Assessment by Monotherapy Products, H2 2016 428

Assessment by Combination Products, H2 2016 429

Number of Products by Top 10 Targets, H2 2016 430

Number of Products by Stage and Top 10 Targets, H2 2016 430

Number of Products by Top 10 Mechanism of Actions, H2 2016 465

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 465

Number of Products by Top 10 Routes of Administration, H2 2016 504

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 504

Number of Products by Top 10 Molecule Types, H2 2016 506

Number of Products by Stage and Top 10 Molecule Types, H2 2016 506

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports